Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.

摘要: Context Androgenetic alopecia is the most common form of in men. Objective To determine efficacy and safety finasteride therapy for patients with androgenetic alopecia. Data Sources MEDLINE, EMBASE, CINAHL, Cochrane Registers, LILACS were searched randomized controlled trials reported any language that evaluated comparison to treatment placebo adults Study Selection Extraction Two reviewers independently eligibility collected data, including assessment methodological quality (Jadad score). Outcome measures included patient self-assessment, hair count, investigator clinical assessment, global photographic adverse effects at short term (≤12 months) long (≥24 months). Heterogeneity was explored by testing a priori hypotheses. Synthesis Twelve studies fulfilled criteria (3927 male patients), 10 which demonstrated Jadad score 3 or more. The proportion reporting an improvement scalp greater than (relative risk [RR], 1.81 [95% confidence interval (CI), 1.42-2.32]; I 2 , 64%) (RR, 1.71 CI, 1.15-2.53]; 16%); both results considered have moderate-quality evidence. number needed treat 1 perceive himself as improved 5.6 (95% 4.6-7.0) 3.4 2.6-5.1) term. Moderate-quality evidence suggested increased mean count from baseline treatment, expressed percentage initial each individual, (mean difference [MD], 9.42% 7.95%-10.90%]; 50%) (MD, 24.3% 17.92%-30.60%]; 0%). Also, 1.80 1.43-2.26]; treat, 3.7 3.2-4.3]; 82%) (moderate-quality evidence). increase erectile dysfunction 2.22 1.03-4.78]; 1%; harm, 82.1 56-231]) possible sexual disturbances 1.39 0.99-1.95]; discontinuing because similar 0.88 0.51-1.49]; 5%) Conclusion suggests daily use oral increases improves appearance, while increasing dysfunction.